Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children's nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline pl
Bristol Myers Squibb Co.
NYSE:BMY ISIN:US1101221083
新聞
日本的大正製藥株式會社(TYO:4535)週三表示,將收購百時美施貴寶公司(Bristol-Myers Squibb Co.)(NYSE:BMY)在亞太地區(不包括中國和日本)價值3.1億美元的非處方藥業務。
###
19,049 公司背景瀏覽
- 本頁瀏覽人次: (過去7日: 13) (過去30日: 49) (自發布以來: 4258)